These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19538530)

  • 1. Advances in individual prediction of methotrexate toxicity: a review.
    Schmiegelow K
    Br J Haematol; 2009 Sep; 146(5):489-503. PubMed ID: 19538530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?
    Kodidela S; Suresh Chandra P; Dubashi B
    Eur J Clin Pharmacol; 2014 Mar; 70(3):253-60. PubMed ID: 24370659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
    Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
    J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
    Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
    Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs.
    de Miguel D; García-Suárez J; Martín Y; Gil-Fernández JJ; Burgaleta C
    Nephrol Dial Transplant; 2008 Dec; 23(12):3762-6. PubMed ID: 18779628
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
    van Kooten Niekerk PB; Schmiegelow K; Schroeder H
    Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.
    Aplenc R; Lange B
    Br J Haematol; 2004 May; 125(4):421-34. PubMed ID: 15142113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?
    D'Angelo V; Ramaglia M; Iannotta A; Addeo R
    Expert Rev Hematol; 2014 Oct; 7(5):517-9. PubMed ID: 25213457
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia.
    Pakakasama S; Kanchanakamhaeng K; Kajanachumpol S; Udomsubpayakul U; Sirachainan N; Thithapandha A; Hongeng S
    Ann Hematol; 2007 Aug; 86(8):609-11. PubMed ID: 17323057
    [No Abstract]   [Full Text] [Related]  

  • 11. [Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use].
    Fujimoto T
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1901-6. PubMed ID: 8978794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
    Lee W; Lockhart AC; Kim RB; Rothenberg ML
    Oncologist; 2005 Feb; 10(2):104-11. PubMed ID: 15709212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
    Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
    Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reaction to methotrexate: pharmacogenetic origin.
    Przekop PR; Tulgan H; Przekop AA; Glantz M
    J Am Osteopath Assoc; 2006 Dec; 106(12):706-7. PubMed ID: 17242415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
    De Mattia E; Toffoli G
    Eur J Cancer; 2009 May; 45(8):1333-51. PubMed ID: 19144510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Individual monitoring of thiopurine and methotrexate treatment].
    Baslund B; Dalhoff KP; Schmiegelow K
    Ugeskr Laeger; 2005 May; 167(20):2177-9. PubMed ID: 15987078
    [No Abstract]   [Full Text] [Related]  

  • 17. Low prevalence of high-dose methotrexate nephropathy in patients with malignancy.
    Mashhadi MA; Kaykhaei MA; Sanadgol H
    Iran J Kidney Dis; 2012 Mar; 6(2):105-9. PubMed ID: 22388607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
    Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
    An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate pulmonary toxicity.
    Lateef O; Shakoor N; Balk RA
    Expert Opin Drug Saf; 2005 Jul; 4(4):723-30. PubMed ID: 16011450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
    Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.